Levacetylleucine

ArtNr	HY-59291-1g
Hersteller	MedChem Express
CAS-Nr.	1188-21-2
Menge	1 g
Quantity options	10 g 10 mM/1 mL 1 g 500 mg
Kategorie	Inhibitors & Compound Libraries Small Molecules
Typ	Inhibitors
Specific against	other
Purity	98.0
Citations	[1]Bremova-Ertl T, et al. Trial of N-Acetyl-l-Leucine in Niemann-Pick Disease Type C[J]. N Engl J Med. 2024 Feb 1;390(5):421-431. \|[2]Sarkar C, et al. N-acetyl-L-leucine: a promising treatment option for traumatic brain injury[J]. Neural Regen Res. 2022 Sep;17(9):1957-1958. \|[3]Günther L, et al. N-acetyl-L-leucine accelerates vestibular compensation after unilateral labyrinthectomy by action in the cerebellum and thalamus[J]. PLoS One. 2015 Mar 24;10(3):e0120891.\|[4]Hegdekar N, et al. N-Acetyl-L-leucine improves functional recovery and attenuates cortical cell death and neuroinflammation after traumatic brain injury in mice[J]. Sci Rep. 2021 Apr 29;11(1):9249.
Smiles	CC(C)C[C@H](NC(C)=O)C(O)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	N-Acetyl-L-leucine
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Natural Products
Manufacturer - Applications	Metabolism-protein/nucleotide metabolism
Manufacturer - Targets	Amino Acid Derivatives
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	173.21
Product Description	Levacetylleucine (N-acetyl-L-leucine), an orally bioavailable and brain-penetrant compound, is an acetylated derivative of amino acid Leucine. Levacetylleucine is the active form of N-acetyl-leucine (NAL). Levacetylleucine attenuates neuronal death and neuroinflammation in the cortical tissue of mice. Levacetylleucine also potentially improves ameliorates lysosomal and metabolic dysfunction. Levacetylleucine improves compensation of postural symptoms after unilateral chemical labyrinthectomy (UL) in rats. Levacetylleucine is promising for research of neurological manifestations of Niemann-Pick disease type C, traumatic brain injury and neurodegeneration prevention[1][2][3][4].
Manufacturer - Research Area	Metabolic Disease; Inflammation/Immunology; Neurological Disease
Solubility	DMSO: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Others
Isoform	Human Endogenous Metabolite
Clinical information	Phase 3

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-59291-1g-safety-datasheet.pdf